Sign up online today & collaborate
or click here to find out more
PharmaMar announced today the opening of a new office in London, UK, to strengthen its commercial activity in the European oncology market.
This affiliate is the fifth office to be opened in Europe, and it will reinforce the presence of PharmaMar in the European territory, which is now supported by the Company´s direct presence in Italy, Germany, France, Switzerland and Spain, where PharmaMar is headquartered.
UK represents one of the top European markets in oncology and a hub for potential research collaborations. With the new team in UK, PharmaMar will aim to provide a stronger medical support to the cancer community and to expand its commercial activity. According to the UK Office for National Statistics, 292,680 new cases of cancer were diagnosed in England in 2013. For male patients, the three most common cancers were prostate, lung and colorectal, and for female patients, these three cancers included breast as well as lung and colorectali.
“This strategic investment shows our commitment to continue growing internationally and to better serve the needs of oncologists and cancer patients in the UK,” pointed out Luis Mora, Managing Director at PharmaMar and President of PharmaMar affiliates.
Headquartered in Madrid, PharmaMar is the world-leading biopharmaceutical company in advancing cancer care through the discovery and development of innovative marine-derived anticancer drugs. The company has a rich pipeline of drug candidates and a robust R&D oncology program. YONDELIS® is commercially available in 78 countries for the treatment of advanced soft tissue sarcomas and for relapsed platinum-sensitive ovarian cancer. PharmaMar develops and commercializes YONDELIS® in urope and has three clinical-stage programs under development for several types of solid and hematological cancers, PM1183, plitidepsin, and PM60184. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland and the United States. To learn more about PharmaMar, please visit us at www.pharmamar.com.
This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.
Carolina Pola – Communications Director
Paula Fdez. Alarcón – Media Relations
Phone: +34 91 444 45 00
Mobile: +34 608 93 36 77
Phone: +34 914444500
Or please visit our website at www.pharmamar.com and www.zeltia.com